India’s Patent Office revokes Sutent cancer drug patent
14-02-2013
India’s Intellectual Property Appellate Board (IPAB) has set aside a decision revoking a Pfizer-licensed patent directed to cancer drug Sutent.
If you have already subscribed please login.
If you have any technical issues please email tech support.
ipab, sugen, sutent, pfizer
